WO2023191676A1 - Antipathogenic material - Google Patents

Antipathogenic material Download PDF

Info

Publication number
WO2023191676A1
WO2023191676A1 PCT/SE2022/050750 SE2022050750W WO2023191676A1 WO 2023191676 A1 WO2023191676 A1 WO 2023191676A1 SE 2022050750 W SE2022050750 W SE 2022050750W WO 2023191676 A1 WO2023191676 A1 WO 2023191676A1
Authority
WO
WIPO (PCT)
Prior art keywords
silicate
calcium silicate
weight
monocalcium
pathogen
Prior art date
Application number
PCT/SE2022/050750
Other languages
French (fr)
Inventor
Håkan ENGQVIST
Original Assignee
Lea Cares Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lea Cares Ab filed Critical Lea Cares Ab
Publication of WO2023191676A1 publication Critical patent/WO2023191676A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/06—Aluminium; Calcium; Magnesium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D1/00—Coating compositions, e.g. paints, varnishes or lacquers, based on inorganic substances
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • C09D5/14—Paints containing biocides, e.g. fungicides, insecticides or pesticides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
    • C09D7/40—Additives
    • C09D7/66—Additives characterised by particle size
    • C09D7/69—Particle size larger than 1000 nm
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/34—Silicon-containing compounds

Definitions

  • the present invention relates to antipathogenic material and the use of such materials.
  • a pathogen is an organism that causes disease. Pathogens include virus, bacteria, and fungi. Pathogens are spread everywhere and in particular in public areas such as on surfaces in transportation vehicles such as buses, cars, subways, etc. and other public areas. Pathogens do not only risk of causing diseases in humans but also animals and can spread in different veterinary settings and medical devices. The need for safe and reliable inactivation, removal, or lysis of viruses, bacteria, and fungi is hence universal.
  • WO 2021/ 177882A1 discloses formulations for use on nails, skin or hair, comprising calcium silicates for local release of calcium and silicon ions.
  • US 2010/0040655 discloses the use of nanoparticles of a compound of the general formula MnXz/, wherein M is i) a metal, or ii) a non-metal and X is iii) a non-metal.
  • the object of the present invention is to solve the problems of the prior art by providing a use of calcium silicate as a pathogen inactivating agent. This is achieved by the invention as defined in the claims.
  • a particulate calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiOa), dicalcium silicate (CaaSiCh), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiCh), as a pathogen inactivating agent as a coating on a device.
  • CaOSiOa monocalcium silicate
  • CaaSiCh dicalcium silicate
  • CasSiOs tricalcium silicate
  • a pathogen inactivating agent as a coating on a device.
  • a particulate calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiOa), dicalcium silicate (CaaSiCh), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiCh), as a pathogen inactivating agent additive in a composition.
  • CaOSiOa monocalcium silicate
  • CaaSiCh dicalcium silicate
  • CasSiOs tricalcium silicate
  • CaOSiCh monocalcium silicate
  • the device is surface in a public transportation vehicle or a surface in a hospital.
  • composition comprises a lotion, cream, or emulsion and the pathogen inactivating agent.
  • the particle size of the particulate calcium silicate is 500-10 pm, or 200-10 pm, or 100-10 pm.
  • the use comprises adding the particulate calcium silicate to a device in a concentration of 30-5 wt% calcium silicate in relation to the weight of the device.
  • the pathogen is influenza virus.
  • Bioglass - or Bioglass 45S5, or calcium sodium phosphosilicate, is a composition of 45 wt% SiOa, 24.5 wt% CaO, 24.5 wt% NaaO, and 6.0 wt% P2O5;
  • ‘Pathogen’ an organism causing disease to its host, can also be referred to as ‘infectious agent’, includes for example virus, bacteria, and fungi; and
  • ‘% by weight’ or “wt%’ the weight fraction of a compound in relation to the total weight of a mixture or composition including the component, expressed in percent.
  • calcium silicate for use as a pathogen inactivating agent.
  • Calcium silicate is a chemical compound comprising calcium and silicate, commonly in the form of a powder. It exists in different forms such as monocalcium silicate (CaOSiO), dicalcium silicate (Ca2SiO4), and tricalcium silicate (CasSiOs). It can also be referred to, and is often traded as, Cai-Sil or Calsil. It is used in different pharmaceutical and food applications as an anti-caking agent, as an antiacid, but it can also be used in other applications for example in agriculture as a source of silicon.
  • CaOSiO monocalcium silicate
  • Ca2SiO4 dicalcium silicate
  • CasSiOs tricalcium silicate
  • a calcium silicate powder material wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiO2), dicalcium silicate (Ca2SiO4), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiO2).
  • the calcium silicate powder can be used for deactivation of virus and other pathogens, i.e. as a pathogen inactivating agent.
  • the invention relates to use of 30-5 % by weight or less based on the total composition of a calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiO2), dicalcium silicate (Ca2SiO4), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiO2), as a pathogen inactivating agent as a coating on a device.
  • the device may be a public transportation vehicle or office furniture or cleaning agent or a device present in a hospital or veterinary setting or a shampoo /balsam /ointment for pets.
  • a particulate calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiOa), dicalcium silicate (CaaSiCh), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiOa), as a pathogen inactivating agent additive in a composition.
  • the composition may comprise a lotion, cream, or emulsion and the pathogen inactivating agent.
  • pathogen inactivating agent refers to an agent that has the ability to render a pathogen unable to infect a host. It can for example be by chemical alteration of lipids or proteins of the pathogen. It can also be via acidic pH that can cause the pathogen to denature. In the present invention a pathogen inactivating agent has the ability to inactivate 50% or more than the present pathogens.
  • the calcium silicate may be present on at least a portion of a surface of a device, wherein the calcium silicate is present in a concentration sufficient to inactivate a pathogen on the surface of the device.
  • the calcium silicate may be present in the form of a coating on the device.
  • the calcium silicate may present in a concentration of 30 % by weight or less, or 10% by weight or less.
  • the calcium silicate may be present in a concentration of 30-5 % by weight, or 30-10 % by weight, or 30-20 % by weight, or 20-5 % by weight, or 20-10 % by weight, or 10-5 % by weight.
  • the solubility of calcium silicates increases with the amount of Ca in the silicate.
  • the present invention takes advantage of the solubility of the calcium silicate and release of different ions such as OH, Ca and silicate to inactivate, remove, or lysis of virus, bacteria, and fungi.
  • the following calcium silicate phases are suitable for use according to the invention: mono calcium silicate (CaOSiOa), di calcium silicate ((CaO ⁇ SiOa) and tri calcium silicate ((CaOjsSiOa).
  • mono calcium silicate CaOSiOa
  • di calcium silicate (CaO ⁇ SiOa)
  • tri calcium silicate ((CaOjsSiOa)
  • the mono calcium silicate phase Preferably the mono calcium silicate phase.
  • Such calcium silicate salts are mildly soluble in water (or humid environment) and provide a source for slow release of the ions
  • the calcium silicate according to the invention is in the form of a powder, or particulate calcium silicate.
  • the particle size, or powder grain size can vary between 10 nm to 800 micrometer, preferably between 10 nm and 50 micrometer, even more preferred 10 nm to 25 micrometer and most preferred 100 nm to 25 micrometer.
  • the average particle size, or grain size is 10-25 pm.
  • the calcium silicate can also be added to industrial products where antipathogenic properties are desired, non-limiting examples includes products where spread of viruses and/or bacteria is a risk e.g. transportation surfaces (buses, cars, subway) or public areas or hospitals.
  • the calcium silicate according to the invention can also be added as an antipathogenic additive composition, for example to a lotion, cream, or emulsion.
  • the calcium silicate can also be added to veterinary products where antipathogenic properties are desired, non-limiting examples includes products where spread of viruses and/or bacteria is a risk e.g. veterinary hospitals or products for veterinary use on animals.
  • the calcium silicate can be added as a powder to be applied on the skin, wounds, hair and / or nails.
  • the calcium silicate powder is distributed in a formulation for it to be well spread when applying the product.
  • the powder can be added to the formulation using ordinary mixing equipment.
  • the formulation may for example comprise a lotion, an emulsion, an oil, etc.
  • the amount of added calcium silicate powder in the formulation is between 0.001 to 30 wt%. Preferably 0.01 to wt3%.
  • a calcium silicate powder according to the invention for use as a medicament.
  • a calcium silicate for use in the treatment of virus infections there is a calcium silicate for use in the treatment of virus infections.
  • the present invention also relates to calcium silicate particles or powder according to the invention for use in prevention or treatment of infections caused by virus, bacteria, fungi, or other pathogens.
  • the concentration of calcium silicate may be 0.1-30 wt%, or 0.1-15 wt%, or 0.1-5 wt%, or 0-1-1 wt%.
  • Treatment of infections does not necessarily mean curative treatment but also encompass inhibition and reduction of the short- and long-term symptoms caused by infections. Hence, ‘treatment’ also encompasses delaying onset of infections, including delaying, preventing onset of symptoms.
  • the method comprises administrating calcium silicate powder according to the invention to a subject for example to skin, to wounds, hair, or nails.
  • the subject is a mammalian subject, for example a human subject.
  • the subject may also be an animal subject such as a pet, for example a dog or a cat.
  • the particles or powder can be administrated locally in the form of a lotion, cream, emulsion, or similar product.
  • Also provided herein is a method of treating or preventing a pathogen at a location in a human.
  • the calcium silicate can be replaced by a bioglass.
  • ‘calcium silicate’ can be exchanged for “bioglass’ and thus in one aspect of the invention there is a bioglass powder material.
  • the bioglass powder can be used for deactivation of virus and other pathogens, i.e. as a pathogen inactivating agent.
  • the invention relates to use of 30%-5 by weight or less based on the total composition of a bioglass as a pathogen inactivating agent in a device.
  • Mono calcium silicate powder (CaOSiOa), with a grain size of below 200 micrometer was mixed with media for an hour. The mixture was centrifuged, the supernatant separated and then added the virus to the supernatant and infected the cells. The results showed a virus inactivation of more than 95%.
  • Mono calcium silicate powder (CaOSiOa), with a grain size of below 100 micrometer was mixed into a lotion to an amount of 15 wt.%.
  • the lotion was then soaked into water at RT for 72 hours (1 gram of material in 10 ml of water). The mixture was centrifuged, the supernatant separated, sterile filtered and then added the virus to the supernatant and infected the cells. The results showed a virus inactivation of more than 70%.
  • Example 3 Mono calcium silicate powder (CaOSiOa), with a grain size of below 100 micrometer was mixed into PMMA to an amount of 15 wt.%. The composite was then soaked into a water at RT for 72 hours (1 gram of material in 10 ml of water). The supernantant was sterile filtered, then added the virus to the supernatant and infected the cells. The results showed a virus inactivation of more than 70%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Public Health (AREA)
  • Agronomy & Crop Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dentistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Disclosed herein are uses of a 30-0.1 % by weight or less based on the total composition of a particulate calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate, dicalcium silicate, and tricalcium silicate, preferably monocalcium silicate, as a pathogen inactivating agent, as a coating on a device, or as a pathogen inactivating agent additive in a composition. The calcium silicate is used for inactivating viruses, bacteria and fungi. The devices and compositions may include surfaces, coatings or slurries such as calcium silicate powder surfaces, coatings or slurries for the inactivation of viruses, bacteria and/or fungi.

Description

Title: Antipathogenic material
Field of invention
The present invention relates to antipathogenic material and the use of such materials.
Background to the invention
A pathogen is an organism that causes disease. Pathogens include virus, bacteria, and fungi. Pathogens are spread everywhere and in particular in public areas such as on surfaces in transportation vehicles such as buses, cars, subways, etc. and other public areas. Pathogens do not only risk of causing diseases in humans but also animals and can spread in different veterinary settings and medical devices. The need for safe and reliable inactivation, removal, or lysis of viruses, bacteria, and fungi is hence universal.
There is a broad need to control pathogens that affect human and animal health as well as agricultural products. Not only is there a need for materials that possess antipathogenic properties for human medicinal therapies, but also for use as surface coatings and/or composites for various medical devices or equipment, examination tables, clothing, filters, masks, gloves, catheters, endoscopic instruments, and the like.
WO 2021/ 177882A1 discloses formulations for use on nails, skin or hair, comprising calcium silicates for local release of calcium and silicon ions.
US 2010/0040655 discloses the use of nanoparticles of a compound of the general formula MnXz/, wherein M is i) a metal, or ii) a non-metal and X is iii) a non-metal.
In the prior art there is still a need for improved methods and materials for the inactivation of pathogens. Summary
The object of the present invention is to solve the problems of the prior art by providing a use of calcium silicate as a pathogen inactivating agent. This is achieved by the invention as defined in the claims.
In one aspect of the invention there is a use of 30-0.1 % by weight or less based on the total composition of a particulate calcium silicate, wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiOa), dicalcium silicate (CaaSiCh), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiCh), as a pathogen inactivating agent as a coating on a device.
In one embodiment of the invention there is a use of 30-5 % by weight or less based on the total composition of a particulate calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiOa), dicalcium silicate (CaaSiCh), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiCh), as a pathogen inactivating agent additive in a composition.
In one embodiment of the invention there is a use wherein the device is surface in a public transportation vehicle or a surface in a hospital.
In one embodiment of the invention there is a use wherein the composition comprises a lotion, cream, or emulsion and the pathogen inactivating agent.
In one embodiment of the invention there is a use wherein the particle size of the particulate calcium silicate is 500-10 pm, or 200-10 pm, or 100-10 pm.
In one embodiment of the invention there is a use wherein the use comprises adding the particulate calcium silicate to a device in a concentration of 30-5 wt% calcium silicate in relation to the weight of the device.
In one embodiment of the invention there is a use wherein the pathogen is influenza virus.
Abbreviations and definitions
‘Monolcalcium silicate’ - CaOSiO;
‘Dicalcium silicate’ - CaaSiCh; Tricalcium silicate’ - CasSiOs;
‘Bioglass’ - or Bioglass 45S5, or calcium sodium phosphosilicate, is a composition of 45 wt% SiOa, 24.5 wt% CaO, 24.5 wt% NaaO, and 6.0 wt% P2O5;
‘Pathogen’ - an organism causing disease to its host, can also be referred to as ‘infectious agent’, includes for example virus, bacteria, and fungi; and
‘% by weight’ or “wt%’ - the weight fraction of a compound in relation to the total weight of a mixture or composition including the component, expressed in percent.
Detailed description
Provided herein is calcium silicate for use as a pathogen inactivating agent.
Calcium silicate is a chemical compound comprising calcium and silicate, commonly in the form of a powder. It exists in different forms such as monocalcium silicate (CaOSiO), dicalcium silicate (Ca2SiO4), and tricalcium silicate (CasSiOs). It can also be referred to, and is often traded as, Cai-Sil or Calsil. It is used in different pharmaceutical and food applications as an anti-caking agent, as an antiacid, but it can also be used in other applications for example in agriculture as a source of silicon.
In a first aspect of the invention there is a calcium silicate powder material, wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiO2), dicalcium silicate (Ca2SiO4), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiO2). The calcium silicate powder can be used for deactivation of virus and other pathogens, i.e. as a pathogen inactivating agent. Hence, the invention relates to use of 30-5 % by weight or less based on the total composition of a calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiO2), dicalcium silicate (Ca2SiO4), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiO2), as a pathogen inactivating agent as a coating on a device. The device may be a public transportation vehicle or office furniture or cleaning agent or a device present in a hospital or veterinary setting or a shampoo /balsam /ointment for pets.
In one aspect of the invention there is a use of 30-5 % by weight or less based on the total composition of a particulate calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiOa), dicalcium silicate (CaaSiCh), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiOa), as a pathogen inactivating agent additive in a composition. The composition may comprise a lotion, cream, or emulsion and the pathogen inactivating agent.
The term ‘pathogen inactivating agent’ refers to an agent that has the ability to render a pathogen unable to infect a host. It can for example be by chemical alteration of lipids or proteins of the pathogen. It can also be via acidic pH that can cause the pathogen to denature. In the present invention a pathogen inactivating agent has the ability to inactivate 50% or more than the present pathogens.
The calcium silicate may be present on at least a portion of a surface of a device, wherein the calcium silicate is present in a concentration sufficient to inactivate a pathogen on the surface of the device. The calcium silicate may be present in the form of a coating on the device. The calcium silicate may present in a concentration of 30 % by weight or less, or 10% by weight or less. The calcium silicate may be present in a concentration of 30-5 % by weight, or 30-10 % by weight, or 30-20 % by weight, or 20-5 % by weight, or 20-10 % by weight, or 10-5 % by weight.
The solubility of calcium silicates (which is a Ca-salt) increases with the amount of Ca in the silicate. Without being bound by any theory, the present invention takes advantage of the solubility of the calcium silicate and release of different ions such as OH, Ca and silicate to inactivate, remove, or lysis of virus, bacteria, and fungi. In one embodiment of the invention there is a use of calcium silicate powder for inactivating of influenza virus.
The following calcium silicate phases are suitable for use according to the invention: mono calcium silicate (CaOSiOa), di calcium silicate ((CaO^SiOa) and tri calcium silicate ((CaOjsSiOa). Preferably the mono calcium silicate phase. Such calcium silicate salts are mildly soluble in water (or humid environment) and provide a source for slow release of the ions
The calcium silicate according to the invention is in the form of a powder, or particulate calcium silicate. In one embodiment the particle size, or powder grain size can vary between 10 nm to 800 micrometer, preferably between 10 nm and 50 micrometer, even more preferred 10 nm to 25 micrometer and most preferred 100 nm to 25 micrometer. In one embodiment the average particle size, or grain size, is 10-25 pm.
The calcium silicate can also be added to industrial products where antipathogenic properties are desired, non-limiting examples includes products where spread of viruses and/or bacteria is a risk e.g. transportation surfaces (buses, cars, subway) or public areas or hospitals.
The calcium silicate according to the invention can also be added as an antipathogenic additive composition, for example to a lotion, cream, or emulsion.
The calcium silicate can also be added to veterinary products where antipathogenic properties are desired, non-limiting examples includes products where spread of viruses and/or bacteria is a risk e.g. veterinary hospitals or products for veterinary use on animals.
The calcium silicate can be added as a powder to be applied on the skin, wounds, hair and / or nails. The calcium silicate powder is distributed in a formulation for it to be well spread when applying the product. The powder can be added to the formulation using ordinary mixing equipment. The formulation may for example comprise a lotion, an emulsion, an oil, etc. In one embodiment the amount of added calcium silicate powder in the formulation is between 0.001 to 30 wt%. Preferably 0.01 to wt3%.
In a second aspect of the invention there is a calcium silicate powder according to the invention for use as a medicament. In one embodiment there is a calcium silicate for use in the treatment of virus infections. The present invention also relates to calcium silicate particles or powder according to the invention for use in prevention or treatment of infections caused by virus, bacteria, fungi, or other pathogens.
When used as a medicament the concentration of calcium silicate may be 0.1-30 wt%, or 0.1-15 wt%, or 0.1-5 wt%, or 0-1-1 wt%.
Treatment of infections’ as used herein does not necessarily mean curative treatment but also encompass inhibition and reduction of the short- and long-term symptoms caused by infections. Hence, ‘treatment’ also encompasses delaying onset of infections, including delaying, preventing onset of symptoms. The method comprises administrating calcium silicate powder according to the invention to a subject for example to skin, to wounds, hair, or nails. The subject is a mammalian subject, for example a human subject. The subject may also be an animal subject such as a pet, for example a dog or a cat. The particles or powder can be administrated locally in the form of a lotion, cream, emulsion, or similar product.
Also provided herein is a method of treating or preventing a pathogen at a location in a human.
As another part of the invention described herein the calcium silicate can be replaced by a bioglass. Hence, herein ‘calcium silicate’ can be exchanged for “bioglass’ and thus in one aspect of the invention there is a bioglass powder material. The bioglass powder can be used for deactivation of virus and other pathogens, i.e. as a pathogen inactivating agent. Hence, the invention relates to use of 30%-5 by weight or less based on the total composition of a bioglass as a pathogen inactivating agent in a device.
All embodiments disclosed herein relate to all aspects of the present invention and all embodiments may be combined unless stated otherwise.
Examples
Example 1
Mono calcium silicate powder (CaOSiOa), with a grain size of below 200 micrometer was mixed with media for an hour. The mixture was centrifuged, the supernatant separated and then added the virus to the supernatant and infected the cells. The results showed a virus inactivation of more than 95%.
Example 2
Mono calcium silicate powder (CaOSiOa), with a grain size of below 100 micrometer was mixed into a lotion to an amount of 15 wt.%. The lotion was then soaked into water at RT for 72 hours (1 gram of material in 10 ml of water). The mixture was centrifuged, the supernatant separated, sterile filtered and then added the virus to the supernatant and infected the cells. The results showed a virus inactivation of more than 70%.
Example 3 Mono calcium silicate powder (CaOSiOa), with a grain size of below 100 micrometer was mixed into PMMA to an amount of 15 wt.%. The composite was then soaked into a water at RT for 72 hours (1 gram of material in 10 ml of water). The supernantant was sterile filtered, then added the virus to the supernatant and infected the cells. The results showed a virus inactivation of more than 70%.

Claims

1. Use of 30-0.1 % by weight or less based on the total composition of a particulate calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiCL), dicalcium silicate (CaaSiCL), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiCL), as a pathogen inactivating agent as a coating on a device.
2. Use of 30-5 % by weight or less based on the total composition of a particulate calcium silicate wherein the calcium silicate is selected from the group of monocalcium silicate (CaOSiCL), dicalcium silicate (CaaSiCL), and tricalcium silicate (CasSiOs), preferably monocalcium silicate (CaOSiCL), as a pathogen inactivating agent additive in a composition.
3. Use according to claim 1 wherein the device is surface in a public transportation vehicle or a surface in a hospital.
4. Use according to claim 2 wherein the composition comprises a lotion, cream, or emulsion and the pathogen inactivating agent.
5. Use according to claim 1 or 2 wherein the particle size of the particulate calcium silicate is 500-10 pm, or 200-10 pm, or 100-10 pm.
6. Use according to any of the preceding claims wherein the use comprises adding the particulate calcium silicate to a device in a concentration of 30-5 wt% calcium silicate in relation to the weight of the device.
7. Use according to any of the preceding claims wherein the pathogen is influenza virus.
PCT/SE2022/050750 2022-03-28 2022-08-15 Antipathogenic material WO2023191676A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2230092 2022-03-28
SE2230092-5 2022-03-28

Publications (1)

Publication Number Publication Date
WO2023191676A1 true WO2023191676A1 (en) 2023-10-05

Family

ID=88203266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2022/050750 WO2023191676A1 (en) 2022-03-28 2022-08-15 Antipathogenic material

Country Status (1)

Country Link
WO (1) WO2023191676A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001794A1 (en) * 2002-06-28 2004-01-01 Withiam Michael C. Compositions comprising odor neutralizing calcium silicate
WO2006078176A1 (en) * 2005-01-18 2006-07-27 Victoria Link Limited Nano-structured silicate, functionalised forms thereof, preparation and uses
CN104262750B (en) * 2014-09-18 2016-11-30 苏州经贸职业技术学院 A kind of antibacterial macromolecular material and preparation method thereof
JP6115002B2 (en) * 2011-03-14 2017-04-19 Dic株式会社 Use of unmodified calcium silicate powder as antibacterial agent
KR20170062081A (en) * 2015-11-27 2017-06-07 이병찬 Compositions comprising odor neutralizing calcium silicate
WO2020070268A1 (en) * 2018-10-05 2020-04-09 Imertech Sas Antimicrobial compositions comprising wollastonite
KR102166042B1 (en) * 2020-06-02 2020-10-15 김태헌 Method of preparing antimicrobial spectable frame and antimicrobial spectable frame prepared by the same
CN111978835A (en) * 2020-09-02 2020-11-24 华容县恒兴建材有限公司 High-wear-resistance ultraviolet curing coating for PVC floor tiles and preparation method thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001794A1 (en) * 2002-06-28 2004-01-01 Withiam Michael C. Compositions comprising odor neutralizing calcium silicate
WO2006078176A1 (en) * 2005-01-18 2006-07-27 Victoria Link Limited Nano-structured silicate, functionalised forms thereof, preparation and uses
JP6115002B2 (en) * 2011-03-14 2017-04-19 Dic株式会社 Use of unmodified calcium silicate powder as antibacterial agent
CN104262750B (en) * 2014-09-18 2016-11-30 苏州经贸职业技术学院 A kind of antibacterial macromolecular material and preparation method thereof
KR20170062081A (en) * 2015-11-27 2017-06-07 이병찬 Compositions comprising odor neutralizing calcium silicate
WO2020070268A1 (en) * 2018-10-05 2020-04-09 Imertech Sas Antimicrobial compositions comprising wollastonite
KR102166042B1 (en) * 2020-06-02 2020-10-15 김태헌 Method of preparing antimicrobial spectable frame and antimicrobial spectable frame prepared by the same
CN111978835A (en) * 2020-09-02 2020-11-24 华容县恒兴建材有限公司 High-wear-resistance ultraviolet curing coating for PVC floor tiles and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "MIWOLL® PRODUCT SHEET Standard Micronized wollastonite series "SUPER"", GEOKOM, 8 November 2020 (2020-11-08), XP093098593, Retrieved from the Internet <URL:https://geokom.com/storage/files/AQXBimrv17SuvgJ6RJtdXU8Ha7i32x5gL9PkG36T.pdf> [retrieved on 20231107] *
BUGA C. ET AL.: "Calcium silicate layer on titanium fabricated by electrospray deposition", MATERIALS SCIENCE AND ENGINEERING C, vol. 98, 2019, pages 401 - 408, XP085611549, DOI: 10.1016/j.msec.2019.01.011 *
BUGA C. ET AL.: "Electrosprayed calcium silicate nanoparticle- coated titanium implant with improved antibacterial activity and osteogenesis", COLLOIDS AND SURFACES B: BIOINTERFACES, vol. 202, no. 111699, 2021, pages 1 - 11, XP086569519, DOI: 10.1016/j.colsurfb.2021.111699 *
GOTLIB ELENA, SADYKOVA DILYARA, VDOVINA TATYANA, GALEEVA LEISAN, SOKOLOVA ALLA: "Evaluation of bactericidal properties of PVC-compositions for linoleum production", E3S WEB OF CONFERENCES, vol. 97, 1 January 2019 (2019-01-01), pages 02001, XP093098588, DOI: 10.1051/e3sconf/20199702001 *

Similar Documents

Publication Publication Date Title
US20090028947A1 (en) Using of nanosilver in poultry, livestock and aquatics industry
JP2003519184A (en) Antimicrobial compositions and methods of use
US20220211034A1 (en) Various uses of the nanoparticulate compound of titanium dioxide functionalized
CN106938046A (en) A kind of antibacterial peptide complex enzyme oral spray
WO2005016363A1 (en) Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil
KR101642537B1 (en) A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
WO2023191676A1 (en) Antipathogenic material
JPH03198747A (en) Disease-preventive feed and feed additive for cattle and pig
JP2009155262A (en) Antiviral agent
AU2011304259C1 (en) Antimicrobial and wound-healing action pharmaceutical composition for external application process of producing the same
JP2008505901A (en) Durable biocide and disinfectant
Doroshenko et al. ECT OF A NANODISPERSION SILICA COMPOSITE WITH POLYHEXAMETHYLENE GUANIDINE HYDROCHLORIDE ON IMMUNOLOGICAL INDICATORS AND INDICATORS OF OXIDATION AND ANTIOXIDANT HOMEOSTASIS IN RATS WITH THERMAL BURN
US8932656B1 (en) Oil blend for skin treatment
KR20060079388A (en) The synthesis of nano inorganic antiviral agent that is effective against sars corona virus and influenza virus
CN105147950A (en) Medical vaseline with sterilization effect
CN111450298A (en) Marine brown algae oligosaccharide herbal atomizing agent and preparation method thereof
JP2006263338A (en) Method for manufacturing sheet for treating bed sore
JP2019069974A (en) Composition comprising arabinogalactan and polyphenols from larch trees
KR20050077887A (en) Nano inorganic antiviral agent that is effective against corona virus and influenza virus
JP4614423B2 (en) Nasal composition for allergic rhinitis
CN114903914B (en) Application of gold nano material in inhibiting coronavirus
CN102007946B (en) Essential oil solid crystalline bactericidal agent and preparation method thereof
CN115089634A (en) Bezoar/essential oil composition for preventing and treating new coronary pneumonia, preparation method and application
Galiveti et al. Moisturizer and COVID-19: Are We Missing a Trick?
Dabbir et al. Clinical management of acute lumpy skin disease in cattle with glycerol mono laurate coated nano zinc oxide.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22935940

Country of ref document: EP

Kind code of ref document: A1